7,647.25

+33.25

+0.44%

52,071.00

+153.00

+0.29%

28,775.75

+241.75

+0.85%

Russell 2000 Futures

2,835.00

+13.70

+0.49%

4.9290

-0.0600

-1.20%

19.42

+2.22

+12.91%

3,921.10

+22.20

+0.57%

78,066.64

+208.05

+0.27%

Crude Oil Dec 26

100.73

-3.39

-3.26%

US Private Equity

10,850.63

-82.20

-0.75%

NasdaqCM - BOATS Real Time Price USD

GeoVax Labs, Inc. (GOVX)

0.1686 -0.0173 (-9.31%)

At close: October 30 at 4:00:01 PM EDT

0.1738 +0.0052 (+3.08%)

Overnight: 10:35:20 PM EST

Loading Chart for GOVX

Chart Range Bar

Interval:

In partnership with ChartIQ

Update - GeoVax Enters Into $1 Million Revolving Loan Agreement

Update - GeoVax Enters Into $1 Million Revolving Loan Agreement

GeoVax Enters Into $1 Million Revolving Loan Agreement

GeoVax Enters Into $1 Million Revolving Loan Agreement

GeoVax to Highlight Next-Generation MVA Vaccine and Manufacturing Advances at World Vaccine Congress Europe 2026

GeoVax to Highlight Next-Generation MVA Vaccine and Manufacturing Advances at World Vaccine Congress Europe 2026

GeoVax Highlights Likely Sustained Clade Ib Mpox Transmission in the United States

GeoVax Highlights Likely Sustained Clade Ib Mpox Transmission in the United States

GeoVax Next-Generation MVA Vaccine Demonstrates Durable Single-Dose Protection in Preclinical Models

GeoVax Next-Generation MVA Vaccine Demonstrates Durable Single-Dose Protection in Preclinical Models

GeoVax and CEPI Enter Agreement to Utilize CEPI Centralised Laboratory Network to Support GEO-MVA Phase 3 Trial

GeoVax and CEPI Enter Agreement to Utilize CEPI Centralised Laboratory Network to Support GEO-MVA Phase 3 Trial

GeoVax Provides Nasdaq Listing Update and Reaffirms Focus on Advancing Strategic Priorities

GeoVax Provides Nasdaq Listing Update and Reaffirms Focus on Advancing Strategic Priorities

GeoVax Welcomes Launch of Global Mpox Vaccine Stockpile, Highlights GEO-MVA Readiness to Support Diversified Global Supply

GeoVax Welcomes Launch of Global Mpox Vaccine Stockpile, Highlights GEO-MVA Readiness to Support Diversified Global Supply

GeoVax Advances GEO-MVA Toward Pivotal Phase 3 Study Implementation

GeoVax Advances GEO-MVA Toward Pivotal Phase 3 Study Implementation

GeoVax Initiates Global Health Outreach to WHO, Africa CDC and Other Agencies Regarding Ebola Vaccine Portfolio Amid Expanding Outbreak

GeoVax Initiates Global Health Outreach to WHO, Africa CDC and Other Agencies Regarding Ebola Vaccine Portfolio Amid Expanding Outbreak

GeoVax Applauds Clinical Validation of Combination Immunotherapy Strategies

GeoVax Applauds Clinical Validation of Combination Immunotherapy Strategies

Mobilize your Website

View Site in Mobile | Classic

Share by: